FP 025

Drug Profile

FP 025

Alternative Names: FP-003; FP-025

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Foresee Pharmaceuticals
  • Class Antiasthmatics
  • Mechanism of Action Matrix metalloproteinase 12 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Dec 2017 Safety and pharmacokinetics data from a phase I trial in Healthy volunteers released by Foresee Pharmaceuticals
  • 04 Dec 2017 Foresee Pharmaceuticals plans a phase II proof-of-concept trial for Asthma in the Netherlands, in 1H 2018
  • 21 Jul 2017 Phase-I clinical trials in Asthma (In volunteers) in Netherlands (PO) (NCT03304964)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top